In this opinion piece, Alloplex CEO Dr. Frank Borriello reflects on a recent gene therapy discontinuation, arguing it reveals a critical misalignment in biotech. He calls for a strategic shift, urging the industry to prioritize patient-centric solutions over chasing trendy technologies.